Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
Lavitrano M, Ianzano L, Bonomo S, Cialdella A, Cerrito MG, Pisano F, Missaglia C, Giovannoni R, Romano G, McLean CM, Voest EE, D'Amato F, Noli B, Ferri GL, Agostini M, Pucciarelli S, Helin K, Leone BE, Canzonieri V, Grassilli E. Lavitrano M, et al. Among authors: helin k. J Pathol. 2020 Feb;250(2):134-147. doi: 10.1002/path.5347. Epub 2019 Dec 2. J Pathol. 2020. PMID: 31518438
Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.
Grassilli E, Narloch R, Federzoni E, Ianzano L, Pisano F, Giovannoni R, Romano G, Masiero L, Leone BE, Bonin S, Donada M, Stanta G, Helin K, Lavitrano M. Grassilli E, et al. Among authors: helin k. Clin Cancer Res. 2013 Jul 15;19(14):3820-31. doi: 10.1158/1078-0432.CCR-12-3289. Epub 2013 May 31. Clin Cancer Res. 2013. PMID: 23729362
A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation.
Grassilli E, Pisano F, Cialdella A, Bonomo S, Missaglia C, Cerrito MG, Masiero L, Ianzano L, Giordano F, Cicirelli V, Narloch R, D'Amato F, Noli B, Ferri GL, Leone BE, Stanta G, Bonin S, Helin K, Giovannoni R, Lavitrano M. Grassilli E, et al. Among authors: helin k. Oncogene. 2016 Aug 18;35(33):4368-78. doi: 10.1038/onc.2015.504. Epub 2016 Jan 25. Oncogene. 2016. PMID: 26804170 Free PMC article.
PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN.
Pastore F, Bhagwat N, Pastore A, Radzisheuskaya A, Karzai A, Krishnan A, Li B, Bowman RL, Xiao W, Viny AD, Zouak A, Park YC, Cordner KB, Braunstein S, Maag JL, Grego A, Mehta J, Wang M, Lin H, Durham BH, Koche RP, Rampal RK, Helin K, Scherle P, Vaddi K, Levine RL. Pastore F, et al. Among authors: helin k. Cancer Discov. 2020 Nov;10(11):1742-1757. doi: 10.1158/2159-8290.CD-20-0026. Epub 2020 Jul 15. Cancer Discov. 2020. PMID: 32669286 Free PMC article.
Antagonism between DNA and H3K27 methylation at the imprinted Rasgrf1 locus.
Lindroth AM, Park YJ, McLean CM, Dokshin GA, Persson JM, Herman H, Pasini D, Miró X, Donohoe ME, Lee JT, Helin K, Soloway PD. Lindroth AM, et al. Among authors: helin k. PLoS Genet. 2008 Aug 1;4(8):e1000145. doi: 10.1371/journal.pgen.1000145. PLoS Genet. 2008. PMID: 18670629 Free PMC article.
TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers.
Damhofer H, Tatar T, Southgate B, Scarneo S, Agger K, Shlyueva D, Uhrbom L, Morrison GM, Hughes PF, Haystead T, Pollard SM, Helin K. Damhofer H, et al. Among authors: helin k. Cell Death Dis. 2024 Apr 17;15(4):273. doi: 10.1038/s41419-024-06654-1. Cell Death Dis. 2024. PMID: 38632238 Free PMC article.
305 results